A detailed history of State Street Corp transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, State Street Corp holds 8,849,588 shares of BCRX stock, worth $67.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,849,588
Previous 9,346,799 5.32%
Holding current value
$67.3 Million
Previous $57.8 Million 16.43%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $3.19 Million - $4.32 Million
-497,211 Reduced 5.32%
8,849,588 $67.3 Million
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $33.6 Million - $55.2 Million
-8,130,545 Reduced 46.52%
9,346,799 $57.8 Million
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $23 Million - $36 Million
4,700,341 Added 36.79%
17,477,344 $88.8 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $11.5 Million - $15.6 Million
2,310,625 Added 22.08%
12,777,003 $76.5 Million
Q3 2023

Nov 14, 2023

SELL
$6.71 - $7.92 $12.1 Million - $14.2 Million
-1,797,591 Reduced 14.66%
10,466,378 $74.1 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $6.09 Million - $7.7 Million
874,346 Added 7.68%
12,263,969 $86.3 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $2.09 Million - $3.11 Million
262,762 Added 2.36%
11,389,623 $95 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $18.1 Million - $24.5 Million
1,722,614 Added 18.32%
11,126,861 $128 Million
Q3 2022

Nov 15, 2022

SELL
$10.79 - $14.81 $17.3 Million - $23.7 Million
-1,600,556 Reduced 14.54%
9,404,247 $118 Million
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $27.9 Million - $63.3 Million
3,542,051 Added 47.46%
11,004,803 $116 Million
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $9.09 Million - $15.5 Million
-786,277 Reduced 9.53%
7,462,752 $121 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $12.8 Million - $17.7 Million
1,143,706 Added 16.1%
8,249,029 $114 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $12.1 Million - $15 Million
852,551 Added 13.63%
7,105,323 $102 Million
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $10 Million - $18.2 Million
-1,056,044 Reduced 14.45%
6,252,772 $98.9 Million
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $27.6 Million - $51 Million
-3,748,163 Reduced 33.9%
7,308,816 $74.3 Million
Q4 2020

Feb 16, 2021

SELL
$3.37 - $8.61 $17.3 Million - $44.1 Million
-5,126,994 Reduced 31.68%
11,056,979 $82.4 Million
Q3 2020

Nov 10, 2020

BUY
$3.43 - $5.53 $2.08 Million - $3.35 Million
605,578 Added 3.89%
16,183,973 $55.6 Million
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $18.7 Million - $55.2 Million
9,832,343 Added 171.11%
15,578,395 $74.2 Million
Q1 2020

May 11, 2020

BUY
$1.6 - $4.11 $9.19 Million - $23.6 Million
5,746,052 New
5,746,052 $11.5 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.